Lilly Receives FDA Warning Letter
Eli Lilly & Company received a warning letter from the US Food and Drug Administration, citing significant deviations from current good manufacturing practices (cGMP) in the manufacture of active pharmaceutical ingredients (APIs) at its facility in Carolina, Puerto Rico.
On February 5, 2010, Eli Lilly & Company (Indianapolis, IN) received a warning letter from the US Food and Drug Administration, citing significant deviations from current good manufacturing practices (cGMP) in the manufacture of active pharmaceutical ingredients (APIs) at its facility in Carolina, Puerto Rico. The APIs, lyspro insulin zinc crystals, are used for the production of Humalog, the company’s fast acting insulin analog, for treating type 1 diabetes in adults.
The letter describes significant cGMP deviations identified during an FDA inspection that was conducted at the company’s API manufacturing facility located at Carolina, Puerto Rico, between July 8 and 31, 2009.
The key deviation cited was that the company failed to adequately investigate critical deviations in 36 batches of API, 24 of which were released for further processing. Furthermore, the company was aware that a similar event at a sister plant had led to that facility’s rejection of the API and extensive cleaning operations. Also, despite the results of studies showing a lack of linearity in the test method, the company failed to assess all affected batches of the APIs that were released for further processing.
Other deviations cited in the warning letter were related to incomplete investigations of stability and potency for these lots and failures to validate changes in cleaning procedures. The letter said the company’s response, on August 21, 2009, did not sufficiently address these concerns. Under the FDA’s new rules put in place last year, the company has 15 days to respond to the warning letter.
Mastering Antibody-Drug Conjugates
December 19th 2024In this episode, we explore BIOVECTRA’s capabilities in antibody-drug conjugate (ADC) manufacturing, from complex conjugation chemistry to synthesis of highly potent payloads. We’ll also showcase how BIOVECTRA’s extensive experience in complex chemistries and specialized small molecule manufacturing gives them a unique perspective, strengthening their approach to ADC production and ensuring clients receive custom solutions across all project stages.
Filter Sizing for Process Optimization in Life Sciences Sterile Filtration
April 24th 2025Bench-scale filterability studies play a critical role in optimizing sterile filtration in biopharmaceutical manufacturing. By guiding the selection and sizing of filters, these studies help streamline processes, improve scalability, and reduce costs. Through data-driven case studies, this paper highlights how the strategic use of pre-filters and membrane materials can maximize throughput and minimize filter fouling.
VERAXA and Voyager to Create Combined Business for Advancing Pipeline of Next-Gen Cancer Therapies
April 23rd 2025The proposed business combination would create a publicly traded, clinical-stage biopharmaceutical company that will focus on developing a pipeline of next-generation cancer therapies.
